ArticleScience immunology2022
Androgen conspires with the CD8
Open access · greenAbstract read
In one paragraph
Article in Science immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 2 pooled it
18.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials.BMC medicine · 2022Pooled it
- Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Nature communications · 2024Trial
- Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026Review
- Sex Steroid Hormone Regulation of T-Cell Function and Antitumor Immunity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis.Science China. Life sciences · 2026Article
- Beyond sex determination: the Y chromosome in male cancers.Nature reviews. Cancer · 2026Review
- Sex differences in non-reproductive cancers: mechanistic roles of sex-hormone signaling.Cell communication and signaling : CCS · 2026Review
- Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy.BMC cancer · 2026Article
- Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.Cancer immunology research · 2026Article
- GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells.Nature cancer · 2026Article
- A pan-cancer single-cell atlas uncovers the role of sex hormones and chromosomes in sex-divergent reprogramming of the tumor microenvironment.Cell communication and signaling : CCS · 2026Article
- Article
- Sex Differences in Colorectal Tumor-Associated T-cell Responses.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Multi-omics analysis reveals AR as a potential prognostic factor and immune-related therapeutic target in gastric cancer.Biochemistry and biophysics reports · 2026Article
- Article
- Highlight on Dr. Rhonda Voskuhl: a pioneer in the exploration of sex differences in the immune response.Biology of sex differences · 2026Article
- Molecular mechanisms and clinical impacts of sex differences in urologic cancers.Discover oncology · 2026Review
- Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.Oral oncology · 2026Article
- Why Is MS a More Frequent Complication of EBV Infection in Females?Immunological reviews · 2026Review
98 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
21 authors at 6 institutions in 1 country.
Hyunwoo KwonPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Johanna M SchaferPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0001-7834-5621
No-Joon SongPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Satoshi KanekoDepartment of Urology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-8462-3245
Anqi LiPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0002-3072-0573
Tong XiaoPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Anjun MaPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0001-6269-398X
Carter AllenPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Komal DasPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Lei ZhouPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Brian RiesenbergPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.
Yuzhou ChangPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0003-4893-1886
Payton WeltgePelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0001-9404-6744
Maria VelegrakiPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0003-3062-9777
David Y OhDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-3310-0994
Lawrence FongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-6428-428X
Qin MaDepartment of Biomedical Informatics, Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-3264-8392
Debasish SundiDepartment of Urology, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0001-6980-4777
Dongjun ChungPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0002-8072-5671
Xue LiDepartment of Urology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Zihai LiPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-James, Columbus, OH 43210, USA.ORCID 0000-0003-4603-927X
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · USUniversity of California, San Francisco · USBoston Children's Hospital · USCedars-Sinai Medical Center · USMedical University of South Carolina · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MThe Role of the Y Chromosome in Bladder Tumor Development, Growth And ProgressionP01CA278732 · NCI · CEDARS-SINAI MEDICAL CENTER · PI SUNGYONG YOU · 2023 to 2026
$10.7MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7MTumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1MMolecular chaperones and immune toleranceR01AI077283 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LI, ZIHAI · 2009 to 2021
$3.7MOvercoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial MetabolismR01CA262388 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$3.6MTargeting GRP94-TGF-beta Pathway for Cancer Immunotherapy SupplementR01CA262069 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2021 to 2025
$2.9MSexual Dimorphism in Bladder CancerR01CA267108 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Xue Sean Li · 2022 to 2026
$2.9MOvercoming hypoxic resistance to anti-cancer therapyR01CA255334 · NCI · OHIO STATE UNIVERSITY · PI DENKO, NICHOLAS C., LI, ZIHAI · 2021 to 2025
$2.9MThe single and same cell 3D atlas of epigenome and transcriptome of the lower urinary tractU01DK131377 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI LI, XUE SEAN · 2021 to 2025
$2.3MThe Six-Family Genes in Cardiovascular Development And DiseaseR01HL136921 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI LI, XUE SEAN · 2017 to 2020
$2.3MMolecular Basis of Sexually Dimorphic Development of the Genital TubercleR01DK110477 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI LI, XUE SEAN · 2017 to 2021
$1.9MNCI NIH HHS P01 CA186866NCI NIH HHS P01 CA278732NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA188419NCI NIH HHS R01 CA213290NCI NIH HHS R01 CA255334NCI NIH HHS R01 CA262069NCI NIH HHS R01 CA262388NCI NIH HHS R01 CA267108NCI NIH HHS R21 CA249701NCI NIH HHS T32 CA090223NHLBI NIH HHS R01 HL136921NIAID NIH HHS K08 AI139375NIAID NIH HHS R01 AI077283NIDDK NIH HHS R01 DK110477NIDDK NIH HHS U01 DK131377
Abstract
Sex bias exists in the development and progression of nonreproductive organ cancers, but the underlying mechanisms are enigmatic. Studies so far have focused largely on sexual dimorphisms in cancer biology and socioeconomic factors. Here, we establish a role for CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAndrogensAnimalsCell DifferentiationFemaleMaleMiceSexismTumor MicroenvironmentAndrogens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.